Citizens Maintains Market Outperform on Stereotaxis, Lowers Price Target to $3
Citizens analyst Daniel Stauder maintains Stereotaxis (AMEX:STXS) with a Market Outperform and lowers the price target from $4 to $3.
Stocks · News reference
Stereotaxis Secures FDA 510(k) Clearance For GenesisX Robotic Magnetic Navigation System
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Buy on Stereotaxis, Lowers Price Target to $3
TD Cowen analyst Joshua Jennings maintains Stereotaxis (AMEX:STXS) with a Buy and lowers the price target from $5 to $3.
Stereotaxis Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $7.670M Miss $8.350M Estimate
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The company reported